Phase 1/2A Data on Transplantation of hESC-Derived RPE Cells for Dry AMD

Christopher D. Riemann, MD

Show Description +

Christopher D. Riemann, MD, shares data from a phase 1/2A study evaluating the safety of transplantation of human embryonic stem cell–derived retinal pigment epithelium cells for the purpose of treating dry AMD. Dr. Riemann educates viewers about the science behind this technique, and outlines interim data from four cohorts of patients.

Posted: 5/13/2020

Keywords:

Clinical Cases

•

drusen

•

Dry age-related macular degeneration (Dry AMD)

•

Retinal Pigment Epithelium (RPE)

•

retina-meeting-recap

•

stem cell therapy

Up Next

Name: Phase 1/2A Data on Transplantation of hESC-Derived RPE Cells for Dry AMD
Uploaded: 2020-05-13T14:04:00+00:00
Description: Christopher D. Riemann, MD, shares data from a phase 1/2A study evaluating the safety of transplantation of human embryonic stem cell–derived retinal pigment epithelium cells for the purpose of treating dry AMD. Dr. Riemann educates viewers about the science behind this technique, and outlines interim data from four cohorts of patients.